https://stock.noler.com/us/stock/safecode-drug-technologies-corp https://stock.noler.com/us/stock/safecode-drug-technologies-corp/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/safecode-drug-technologies-corp/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/safecode-drug-technologies-corp/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/safecode-drug-technologies-corp/asset-impairment-charges https://stock.noler.com/us/stock/safecode-drug-technologies-corp/cash-and-equivalents https://stock.noler.com/us/stock/safecode-drug-technologies-corp/cash-flow-breakdown https://stock.noler.com/us/stock/safecode-drug-technologies-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/safecode-drug-technologies-corp/common-stock-value https://stock.noler.com/us/stock/safecode-drug-technologies-corp/convertible-notes-payable-current https://stock.noler.com/us/stock/safecode-drug-technologies-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/safecode-drug-technologies-corp/current-assets https://stock.noler.com/us/stock/safecode-drug-technologies-corp/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/safecode-drug-technologies-corp/current-income-tax-expense-benefit https://stock.noler.com/us/stock/safecode-drug-technologies-corp/current-liabilities https://stock.noler.com/us/stock/safecode-drug-technologies-corp/debt-convertible-beneficial-conversion-feature https://stock.noler.com/us/stock/safecode-drug-technologies-corp/debt-convertible-interest-expense https://stock.noler.com/us/stock/safecode-drug-technologies-corp/debt-unamortized-discount https://stock.noler.com/us/stock/safecode-drug-technologies-corp/deferred-offering-costs https://stock.noler.com/us/stock/safecode-drug-technologies-corp/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/safecode-drug-technologies-corp/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/safecode-drug-technologies-corp/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/safecode-drug-technologies-corp/development-stage-enterprise-deficit-accumulated-during-development-stage https://stock.noler.com/us/stock/safecode-drug-technologies-corp/due-from-related-parties https://stock.noler.com/us/stock/safecode-drug-technologies-corp/due-from-related-parties-current https://stock.noler.com/us/stock/safecode-drug-technologies-corp/due-to-related-parties-current https://stock.noler.com/us/stock/safecode-drug-technologies-corp/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/safecode-drug-technologies-corp/fees-and-commissions https://stock.noler.com/us/stock/safecode-drug-technologies-corp/financing-cash-flow https://stock.noler.com/us/stock/safecode-drug-technologies-corp/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/safecode-drug-technologies-corp/income-tax https://stock.noler.com/us/stock/safecode-drug-technologies-corp/income-taxes-paid https://stock.noler.com/us/stock/safecode-drug-technologies-corp/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/safecode-drug-technologies-corp/increase-decrease-in-intangible-assets-current https://stock.noler.com/us/stock/safecode-drug-technologies-corp/increase-decrease-in-marketable-securities-restricted https://stock.noler.com/us/stock/safecode-drug-technologies-corp/intangible-assets-current https://stock.noler.com/us/stock/safecode-drug-technologies-corp/interest-expense https://stock.noler.com/us/stock/safecode-drug-technologies-corp/interest-paid https://stock.noler.com/us/stock/safecode-drug-technologies-corp/investing-cash-flow https://stock.noler.com/us/stock/safecode-drug-technologies-corp/legal-fees https://stock.noler.com/us/stock/safecode-drug-technologies-corp/license-costs https://stock.noler.com/us/stock/safecode-drug-technologies-corp/marketable-securities-current https://stock.noler.com/us/stock/safecode-drug-technologies-corp/net-change-in-cash https://stock.noler.com/us/stock/safecode-drug-technologies-corp/net-income https://stock.noler.com/us/stock/safecode-drug-technologies-corp/noncash-or-part-noncash-acquisition-intangible-assets-acquired https://stock.noler.com/us/stock/safecode-drug-technologies-corp/noncash-or-part-noncash-acquisition-investments-acquired https://stock.noler.com/us/stock/safecode-drug-technologies-corp/noninterest-expense-offering-cost https://stock.noler.com/us/stock/safecode-drug-technologies-corp/operating-cash-flow https://stock.noler.com/us/stock/safecode-drug-technologies-corp/operating-costs-and-expenses https://stock.noler.com/us/stock/safecode-drug-technologies-corp/operating-expenses https://stock.noler.com/us/stock/safecode-drug-technologies-corp/operating-income https://stock.noler.com/us/stock/safecode-drug-technologies-corp/operating-loss-carryforwards https://stock.noler.com/us/stock/safecode-drug-technologies-corp/other-cost-and-expense-operating https://stock.noler.com/us/stock/safecode-drug-technologies-corp/other-income https://stock.noler.com/us/stock/safecode-drug-technologies-corp/paid-in-capital-shares-issued-issuance-costs https://stock.noler.com/us/stock/safecode-drug-technologies-corp/pretax-income https://stock.noler.com/us/stock/safecode-drug-technologies-corp/proceeds-from-convertible-debt https://stock.noler.com/us/stock/safecode-drug-technologies-corp/proceeds-from-related-party-debt https://stock.noler.com/us/stock/safecode-drug-technologies-corp/proceeds-from-repayments-of-related-party-debt https://stock.noler.com/us/stock/safecode-drug-technologies-corp/proceeds-from-sale-and-maturity-of-marketable-securities https://stock.noler.com/us/stock/safecode-drug-technologies-corp/proceeds-from-stock-issued https://stock.noler.com/us/stock/safecode-drug-technologies-corp/professional-fees https://stock.noler.com/us/stock/safecode-drug-technologies-corp/public-float https://stock.noler.com/us/stock/safecode-drug-technologies-corp/receivable-from-officers-and-directors-for-issuance-of-capital-stock https://stock.noler.com/us/stock/safecode-drug-technologies-corp/repayments-of-related-party-debt https://stock.noler.com/us/stock/safecode-drug-technologies-corp/revenue https://stock.noler.com/us/stock/safecode-drug-technologies-corp/shareholders-equity https://stock.noler.com/us/stock/safecode-drug-technologies-corp/shares-authorized https://stock.noler.com/us/stock/safecode-drug-technologies-corp/shares-issued https://stock.noler.com/us/stock/safecode-drug-technologies-corp/shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/safecode-drug-technologies-corp/stock-based-compensation https://stock.noler.com/us/stock/safecode-drug-technologies-corp/stock-issued-new-shares-sold https://stock.noler.com/us/stock/safecode-drug-technologies-corp/stock-issued-shares-issued-value-issued-for-services https://stock.noler.com/us/stock/safecode-drug-technologies-corp/tax-credit-carryforward-amount https://stock.noler.com/us/stock/safecode-drug-technologies-corp/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/safecode-drug-technologies-corp/tax-rate-reconciliation-tax-settlements https://stock.noler.com/us/stock/safecode-drug-technologies-corp/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/safecode-drug-technologies-corp/total-assets https://stock.noler.com/us/stock/safecode-drug-technologies-corp/total-liabilities https://stock.noler.com/us/stock/safecode-drug-technologies-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/safecode-drug-technologies-corp/trading-securities-cost https://stock.noler.com/us/stock/safecode-drug-technologies-corp/trading-securities-fair-value-disclosure https://stock.noler.com/us/stock/safecode-drug-technologies-corp/trading-securities-realized-loss https://stock.noler.com/us/stock/safecode-drug-technologies-corp/trading-securities-unrealized-holding-loss https://stock.noler.com/us/stock/safecode-drug-technologies-corp/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/safecode-drug-technologies-corp/weighted-average-number-of-share-outstanding-basic-and-diluted